University of Texas's MD Anderson Cancer: Axi-Cel CAR T Cell Therapy Shows Enhanced Responses and Continued Benefit for High-Risk Lymphoma Patients
December 13, 2021
December 13, 2021
HOUSTON, Texas, Dec. 13 (TNSJou) -- The University of Texas's MD Anderson Cancer Center issued the following news release:
* * *
MD Anderson study results presented at American Society of Hematology meeting
* * *
Three clinical studies led by researchers at The University of Texas MD Anderson Cancer Center demonstrated enhanced responses for patients with high-risk lymphoma treated with axicabtagene ciloleucel (axi-cel) chimeric antigen re . . .
* * *
MD Anderson study results presented at American Society of Hematology meeting
* * *
Three clinical studies led by researchers at The University of Texas MD Anderson Cancer Center demonstrated enhanced responses for patients with high-risk lymphoma treated with axicabtagene ciloleucel (axi-cel) chimeric antigen re . . .